You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 2, 2024

VIAGRA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


Which patents cover Viagra, and when can generic versions of Viagra launch?

Viagra is a drug marketed by Viatris and is included in one NDA.

The generic ingredient in VIAGRA is sildenafil citrate. There are twenty drug master file entries for this compound. Sixty-eight suppliers are listed for this compound. Additional details are available on the sildenafil citrate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Viagra

A generic version of VIAGRA was approved as sildenafil citrate by CHARTWELL RX on November 6th, 2012.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for VIAGRA?
  • What are the global sales for VIAGRA?
  • What is Average Wholesale Price for VIAGRA?
Drug patent expirations by year for VIAGRA
Drug Prices for VIAGRA

See drug prices for VIAGRA

Drug Sales Revenue Trends for VIAGRA

See drug sales revenues for VIAGRA

Recent Clinical Trials for VIAGRA

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
University Hospital, RouenPhase 3
Pia WintermarkPhase 2
Al-Azhar UniversityPhase 2

See all VIAGRA clinical trials

Pharmacology for VIAGRA
Paragraph IV (Patent) Challenges for VIAGRA
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
VIAGRA Tablets sildenafil citrate 25 mg and 50 mg 020895 1 2004-11-19
VIAGRA Tablets sildenafil citrate 100 mg 020895 1 2004-10-25

US Patents and Regulatory Information for VIAGRA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-002 Mar 27, 1998 AB RX Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-003 Mar 27, 1998 AB RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for VIAGRA

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-002 Mar 27, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-002 Mar 27, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-003 Mar 27, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-001 Mar 27, 1998 ⤷  Sign Up ⤷  Sign Up
Viatris VIAGRA sildenafil citrate TABLET;ORAL 020895-003 Mar 27, 1998 ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for VIAGRA

See the table below for patents covering VIAGRA around the world.

Country Patent Number Title Estimated Expiration
United Kingdom 9311920 ⤷  Sign Up
Egypt 19651 Process for preparing of pyrazolopyrimidinone antianginal agents ⤷  Sign Up
Luxembourg 90360 ⤷  Sign Up
Norway 178029 ⤷  Sign Up
China 1124926 ⤷  Sign Up
New Zealand 314110 The use of pyrazolopyrimidinone derivatives in preparing pharmaceutical compositions ⤷  Sign Up
Ecuador SP941102 PIRAZOLOPIRIMIDINONAS PARA EL TRATAMIENTO DE LA IMPOTENCIA ⤷  Sign Up
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for VIAGRA

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
0463756 SPC/GB99/004 United Kingdom ⤷  Sign Up PRODUCT NAME: SILDENAFIL AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE CITRATE SALT; REGISTERED: CH 54642 19980622; UK EU/1/98/077/001 19980914; UK EU/1/98/077/002 19980914; UK EU/1/98/077/003 19980914; UK EU/1/98/077/004 19980914; UK EU/1/98/077/005 19980914; UK EU/1/98/077/006 19980914; UK EU/1/98/077/007 19980914; UK EU/1/98/077/008 19980914; UK EU/1/98/077/009 19980914; UK EU/1/98/077/010 19980914; UK EU/1/98/077/011 19980914; UK EU/1/98/077/012 19980914
0463756 99C0007 Belgium ⤷  Sign Up PRODUCT NAME: SILDENAFIL, NATL REGISTRATION NO/DATE: EU/1/98/077/001 19980914; FIRST REGISTRATION: CH 54642 19980622
0463756 300048 Netherlands ⤷  Sign Up PRODUCT NAME: ZOLMITRIPTANUM, DESGEWENST IN DE VORM VAN EEN FYSIOLOGISCH AANVAARDBAAR ZOUT OF VAN EEN SOLVAAT; NATL. REGISTRATION: RVG 21079 RVG 21080 19970925; FIRST REGISTRATION: PL 12619/0116 19970307
0463756 5/1999 Austria ⤷  Sign Up PRODUCT NAME: ''SILDENAFIL'' UND DESSEN PHARMAZEUTISCH ANNEHMBAREN SALZE, EINSCHLIESSLICH DES CITRATS; NAT. REGISTRATION NO/DATE: EU/1/98/077/001 - EU/1/98/077/012 19980914; FIRST REGISTRATION: LI 54642 01-54642 03 19980622
0463756 C990005 Netherlands ⤷  Sign Up PRODUCT NAME: SILDENAFIL, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AAN- VAARDBAAR ZOUT, IN HET BIJZONDER SILDENAFIL CITRAAT; NATL REGISTRATION NO/DATE: EU/1/98/077/001-012 19980914; FIRST REGISTRATION: CH 54642 19980622
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.